

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Airomir[®] Autohaler, pressurised inhalation suspension

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each actuation of Airomir Autohaler device delivers Salbutamol Sulfate Ph Eur equivalent to Salbutamol 100 micrograms into the mouthpiece of the adapter.

Excipient(s) with known effect

Each metered dose contains 4 mg alcohol (ethanol).

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Pressurised inhalation suspension.

Airomir Autohaler device is a breath actuated inhaler for bronchodilator inhalation therapy which automatically releases the metered dose of medication during a patient's inhalation through the mouthpiece and overcomes the need for patients to have good manual co-ordination.

Airomir Autohaler device contains a new propellant and does not contain chlorofluorocarbons (CFCs).

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Airomir Autohaler is indicated in adults, adolescents and children aged 4 to 11 years.

For babies and children under 4 years of age, see section 4.2 and 5.1.

Airomir Autohaler device is indicated in the management of bronchial asthma, for the relief of wheezing and shortness of breath used on an as required basis. Airomir Autohaler device may be used as necessary to relieve attacks of acute dyspnoea and may be used prophylactically before exertion or to prevent exercise-induced asthma.

Airomir Autohaler device may also be used in the treatment of the reversible component of airways obstruction.

4.2 Posology and method of administration

Posology

Adults

For the relief of wheezing, shortness of breath and attacks of acute dyspnoea in patients with asthma, or the reversible component of airways obstruction, one or two inhalations may be administered as a single dose.

For prophylaxis of exercise-induced asthma, two inhalations before exercise.

For chronic therapy, two inhalations up to four times a day.

Paediatric Population

Relief of acute bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms). The dose may be increased to two inhalations if required.

Children aged 12 years and over: Dose as per adult population.

Prevention of allergen or exercise-induced bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms) before challenge or exertion. The dose may be increased to two inhalations if required.

Children aged 12 years and over: Dose as per adult population.

Chronic Therapy

The usual dosage for children under the age of 12 years: up to two inhalations 4 times daily.

Children aged 12 years and over: Dose as per adult population

Elderly

No special dosage recommendations are made for elderly patients.

For all patients, the maximum recommended dose should not exceed eight inhalations in 24 hours. With repetitive dosing, inhalations should not usually be repeated more often than every 4 hours.

Method of administration

For Inhalation Use.

4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

Airomir Autohaler device is contraindicated for use in the management of premature labour and threatened abortion.

4.4 Special warnings and precautions for use

Patients should be instructed in the proper use of the inhaler and their technique checked, to ensure that the active substance reaches the target areas within the lungs. Patients should be warned they may experience a different taste on inhalation compared to their previous inhaler.

The management of asthma should normally follow a stepwise programme, and the patient's response should be monitored clinically and by lung function tests. Increasing use of short-acting bronchodilators, in particular β_2 -agonists to control symptoms, indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed. Patients with persistent asthma should receive optimal anti-inflammatory basic therapy with corticosteroids.

Sudden and progressive deterioration in asthma control is potentially life threatening and consideration should be given to increasing or starting oral and/or inhaler corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.

The dosage or frequency of administration should only be increased on medical advice. The patient should be advised to seek medical advice if a previously effective dose ceases to be effective for at least three hours, and/or their asthma seems to be worsening.

Patients requiring long-term management with Airomir Autohaler device should be kept under regular surveillance.

Salbutamol should be administered cautiously to patients with thyrotoxicosis, coronary insufficiency, hypertrophic obstructive cardiomyopathy, arterial hypertension, tachyarrhythmias, in concomitant use of cardiac glycosides or diabetes mellitus.

Potentially serious hypokalaemia has been reported in patients taking β_2 -agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics, long-term laxatives and by hypoxia. Extra care should therefore be taken if β_2 -agonists are used in these groups of patients and it is recommended that serum potassium levels should be monitored in such situations.

Care should be taken when treating acute asthma attacks or exacerbation of severe asthma as increased serum lactate levels, and rarely, lactic acidosis have been reported after high doses of salbutamol have been used in emergency situations. This is reversible on reducing the dose of salbutamol (see section 4.9 Overdose).

Unwanted stimulation of cardiac adrenoceptors can occur in patients taking β_2 -agonist therapy.

Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with β -agonists. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmias or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be either respiratory or cardiac in origin.

As with other inhalation therapy, the potential for paradoxical bronchospasm should be considered. If this occurs, the Airomir Autohaler should be discontinued immediately and

alternative therapy given. Solutions which are not of neutral pH may rarely cause paradoxical bronchospasm in some patients.

Salbutamol and non-selective β -antagonists such as propranolol should not usually be prescribed together.

In common with other β -agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Patients with diabetes may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of glucocorticoids can exaggerate this effect.

Severe exacerbations of asthma must be treated in the normal way.

Excipient(s)

Ethanol

The small amount of alcohol in this medicine will not have any noticeable effects.

4.5 Interaction with other medicinal products and other forms of interaction

Propranolol and other non-cardioselective β -adrenoceptor blocking agents antagonise the effects of salbutamol and should not usually be prescribed together.

Monoamine oxidase inhibitors, tricyclic antidepressants and digoxin increase the risk of cardiovascular effects.

Patients should be instructed to discontinue salbutamol for at least 6 hours before an intended anaesthesia with halogenic anaesthetics, wherever possible.

Hypokalaemia occurring with β_2 -agonist therapy may be exacerbated by treatment with xanthines, steroids, diuretics and long-term laxatives.

Because Airomir contains ethanol there is a theoretical potential for interaction in patients taking disulfiram or metronidazole. The amount of ethanol in Airomir is small but it may be enough to precipitate a reaction in some sensitive patients.

4.6 Fertility, pregnancy and lactation

Pregnancy

Airomir

There is no experience of this product in pregnancy and lactation in humans. It should not be used in pregnancy and lactation unless the expected benefit to the mother is thought to outweigh any risk to the foetus or neonate.

Propellant 134a

There is no documented evidence of the use of salbutamol formulated with propellant HFA-134a in pregnant or lactating women.

Salbutamol

The safe use of inhaled salbutamol during pregnancy has not been established but it has been in widespread use for many years in human beings without apparent ill consequence. Rare

reports of various congenital anomalies following intrauterine exposure to salbutamol (including cleft palate, limb defects and cardiac disorders) have been received. Some of the mothers were taking multiple medications during their pregnancies.

Experience on the use of β -sympathomimetics during early pregnancy indicates no harmful effect at the doses ordinarily used for inhalation therapy. High systemic doses at the end of pregnancy can cause inhibition of labour and may induce β_2 - specific foetal/neonatal effects like tachycardia and hypoglycaemia. Inhalation therapy at recommended doses is not expected to induce these harmful side effects at the end of pregnancy.

Breast-feeding

As salbutamol is probably secreted in breast milk, its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.

Salbutamol inhalation is contraindicated in treatment of threatened abortion or premature labour.

Fertility

There is no information on the effects of salbutamol on human fertility. There were no adverse effects on fertility in animals (see section 5.3).

4.7 Effects on ability to drive and use machines

Airomir may cause dizziness. If you are affected do not drive or operate machinery.

4.8 Undesirable effects

Based on the MedDRA system organ class and frequencies, adverse reactions are listed in the table below.

Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1\ 000$ to $< 1/100$), rare ($\geq 1/10\ 000$ to $< 1/1\ 000$), very rare ($\leq 1/10\ 000$ including isolated reports) and not known (cannot be estimated from the available data).

<u>System organ class</u>	<u>Frequency</u>	<u>Symptom</u>
Immune system disorders	Very rare	Hypersensitivity reactions (angioedema, urticaria, bronchospasm, hypotension and collapse)
Metabolism and nutrition disorders	Rare	Hypokalaemia (especially in combination with xanthine derivatives, corticosteroids and diuretics) increased serum lactate levels and acidosis lactic
Psychiatric disorders	Common	Tenseness

	Rare	Sleep disturbances and hallucinations (especially in children)
	Very rare	Insomnia
Nervous system disorders	Common	Headache, Dizziness, Tremor muscle
Cardiac disorders	Rare	Palpitations, tachycardia
	Very rare	Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles) - especially if used concomitantly with other β_2 -agonists
	Not known	Myocardial ischaemia (see section 4.4)
Vascular disorders	Rare	Peripheral vasodilatation
Respiratory, thoracic and mediastinal disorders	Rare	Throat irritation
	Very rare	Paradoxical bronchospasm (with an immediate increase in wheezing after dosing) (As with other inhalation therapy, paradoxical bronchospasm may occur immediately after dosing. If this occurs, Airomir Inhaler should be discontinued immediately and, if needed, an alternative therapy instituted.)
Gastrointestinal disorders	Rare	Mouth irritation, nausea, vomiting, dry mouth, sore mouth
Skin and subcutaneous tissue disorders	Very rare	Pruritus
Musculoskeletal and connective tissue disorders	Uncommon	Myalgia, muscle cramps
	Very rare	Fine tremor (particularly of hands)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms

Overdosage may result in skeletal muscle tremor, tachycardia, tenseness, headache, and peripheral vasodilatation.

Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored.

Hyperglycaemia, agitation and hyperactivity have also been reported following overdose with salbutamol.

Lactic acidosis has been reported very rarely in patients receiving intravenous or nebulised salbutamol therapy for the treatment of acute asthma exacerbation.

Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.

Treatment

Asthmatic patients: Consideration should be given to discontinuation of treatment. Monitor biochemical abnormalities, particularly hypokalaemia which should be treated with potassium replacement where necessary. β -adrenoceptor antagonists, even β_1 -selective antagonists, are potentially life-threatening and should be avoided.

Non-asthmatic patients: Monitor and correct biochemical abnormalities, particularly hypokalaemia.

The preferred antidote for overdosage with salbutamol is a cardioselective β -adrenoceptor blocking agent but due care and attention should be used in administering beta-blocking drugs in patients with a history of bronchospasm, as these drugs are potentially life-threatening. A non-selective β -adrenoceptor antagonist (e.g. nadolol, propranolol) will competitively reverse both hypokalaemia and tachycardia (β_1 -selective drugs will be largely ineffective).

The treatment of lactic acidosis in cases of salbutamol overdose should be undertaken in a specialist intensive care unit. Salbutamol therapy should be discontinued and appropriate supportive therapy should be commenced to treat the underlying condition. Lactic acidosis is treated indirectly by correcting the underlying causes and not by any treatment aimed directly at correction of lactic acidosis itself.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: selective β_2 -adrenoreceptor agonists
ATC code: R03AC02

Salbutamol is a sympathomimetic agent which has a selective action on β_2 -adrenoceptors of bronchial muscle. At therapeutic doses, salbutamol acts on the β_2 -adrenoceptors of bronchial muscle with little or no action on the β_2 -adrenoceptors of cardiac muscle. Salbutamol provides short acting (4 to 6 hours) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction.

Special Patient Populations

Children < 4 years of age

Paediatric clinical studies conducted at the recommended dose (SB020001, SB030001, SB030002), in patients < 4 years with bronchospasm associated with reversible obstructive airways disease, show that Airomir Autohaler has a safety profile comparable to that in children > 4 years, adolescents and adults.

5.2 Pharmacokinetic properties

Salbutamol is readily absorbed from the gastro-intestinal tract, but the systemic absorption of the inhaled drug substance is low. The action of inhaled salbutamol depends on direct stimulation of receptors in the lung. Onset of action is usually within 10 minutes of inhalation and lasts 4-6 hours in most patients.

Salbutamol is subject to first-pass metabolism in the liver; about half is excreted in the urine as an inactive sulfate conjugate. It does not appear to be metabolised in the lung and therefore its fate following inhalation therapy depends on the delivery method used, which determines the proportion of salbutamol inhaled relative to the proportion inadvertently swallowed. It has been suggested that the slightly extended half-life following inhalation may reflect slow removal of active drug from the lungs.

5.3 Preclinical safety data

Propellant 134a

In animal studies propellant 134a has been shown to have no significant pharmacological effects other than at very high exposure concentrations, when narcosis and a relatively weak cardiac sensitising effect were found. The potency of the cardiac sensitisation was less than that of CFC-11 (trichlorofluoromethane).

In studies to detect toxicity, repeated high dose levels of propellant 134a indicated that safety margins based on systemic exposure would be of the order 2200, 1314 and 381 for mouse, rat and dog with respect to humans.

There are no reasons to consider propellant 134a as a potential mutagen, clastogen or carcinogen judged from in vitro and in vivo studies including long-term administration by inhalation in rodents.

Airomir Autohaler Safety studies with the Salbutamol Sulfate CFC-Free formulation in rat and dog showed few adverse effects. These occurred at high doses and were consistent with the known effects of salbutamol inhalation.

In an oral fertility and general reproductive performance study in rats at doses of 2 and 50 mg/kg/day, with the exception of a reduction in number of weanlings surviving to day 21 post partum at 50 mg/kg/day, there were no adverse effects on fertility, embryofoetal development, litter size, birth weight or growth rate.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

The excipients in Airomir Autohaler device are Oleic Acid, Ph Eur; Ethanol, BP; and Propellant 134a.

Airomir Autohaler device contains a new propellant and does not contain chlorofluorocarbons (CFCs).

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store below 30°C. Store in the original package.

Storage in direct sunlight or heat should be avoided. Protect from frost.

6.5 Nature and contents of container

Airomir Autohaler device contains 200 metered doses.

6.6 Special precautions for disposal

The patient should read the instruction leaflet before use.

As the canister is pressurised, no attempt should be made to puncture or dispose of it by burning.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Teva UK Limited,
Ridings Point,
Whistler Drive,
Castleford,
WF10 5HX,
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 00289/1411

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

11th August 1997 – 29 September 2007

10 DATE OF REVISION OF THE TEXT

12/07/2024